Log in or Sign up for Free to view tailored content for your specialty!
Hidradenitis Suppurativa News
31% of women of childbearing age prescribed teratogenic drugs for hidradenitis suppurativa
Women of childbearing age with hidradenitis suppurativa are often prescribed teratogenic medications, and the majority do not receive physician-led counsel on how these medications could impact childbearing, according to published data.
EMA accepts marketing authorization for bimekizumab for hidradenitis suppurativa
The European Medicines Agency has accepted for review the marketing authorization application for bimekizumab for moderate to severe hidradenitis suppurativa treatment in adults, UCB announced in a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Comorbidities, costs among patients with hidradenitis suppurativa continue to rise
Comorbidities, health care utilization and costs are increasing for patients with hidradenitis suppurativa, prompting a need for better disease management, according to a study.
Guide to prescribing methotrexate to pediatric patients with inflammatory skin diseases
In a panel-led project, 23 experts created a comprehensive guide for the long-term management of inflammatory skin diseases in pediatric patients treated with methotrexate.
Crohn’s disease more prevalent among pediatric patients with hidradenitis suppurativa
Pediatric patients with hidradenitis suppurativa are more than four times more likely to have Crohn’s disease compared with those without hidradenitis suppurativa, according to a study.
Patients with overweight, obesity benefit from increased dose of adalimumab
Increased adalimumab dosage may improve disease severity in patients with overweight or obesity with moderate to severe hidradenitis suppurativa, according to a study.
Targeting B cells, plasma cells may aid hidradenitis suppurativa treatment
Patients with hidradenitis suppurativa saw improvement with fostamatinib treatment, showing that targeting B cells and plasma cells could be an upcoming strategy in treating the disease, according to a study.
European Commission approves Cosentyx for adults with hidradenitis suppurativa
The European Commission has approved Cosentyx in the European Union for the treatment of moderate to severe hidradenitis suppurativa in adults who do not respond to conventional therapy, Novartis announced in a press release.
FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar
The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.
Novel treatment paradigm bests standard of care in hidradenitis suppurativa
A novel treatment paradigm was associated with improved disease severity and patient satisfaction compared with standard of care in a cohort of patients with hidradenitis suppurativa, according to a study.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read